Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A compound pharmaceutical composition for treating type II diabetes or metabolic syndrome

A technology of composition and medicine, applied in the field of medicine, can solve the problems of not being able to improve IR research reports, etc.

Active Publication Date: 2016-01-20
CHINA PHARM UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are clinical reports of SAR treating diabetic complications of lower extremity arteriosclerosis obliterans, there is no research report that can improve IR

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound pharmaceutical composition for treating type II diabetes or metabolic syndrome
  • A compound pharmaceutical composition for treating type II diabetes or metabolic syndrome
  • A compound pharmaceutical composition for treating type II diabetes or metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] In Vitro Cell Culture Studies of Hepatocytes

[0038] "Hepatocyte 5-HT synthesis system, 5-HT 2A,2B Receptor gene expression, GLUT gene expression, changes upon DEX or OA stimulation; and inhibition of 5-HT synthesis or blockade of 5-HT 2A,2B receptor (5-HT 2A,2B R) on the improvement of IR caused by DEX or OA" research results.

[0039] 1.1 Experimental method

[0040] (1) Cell culture

[0041] The rat BRL-3A liver cell line was cultured in vitro, and the experiment was completed at the 10-20 generation of cell passage. Cells were cultured at 37°C with 5% CO 2 cultured in PRMI-1640 medium containing 10% fetal bovine serum, and combined with penicillin / lianmycin for antibacterial. Cell seeding concentration 5×10 5 One per bottle, after 24 hours of culture, the drug can be administered when the cell proliferation reaches 70-80% of the bottom area of ​​the bottle. IR cell models were stimulated with dexamethasone (DEX) or oleic acid (OA) respectively. DEX-stimula...

Embodiment 2

[0075] Animal Experimental Research - Rat IR and Diabetes Model Induced by DEX

[0076] Compare the therapeutic effect of SAR combined with pCPA, CDP, BSA, and each alone on DEX-induced IR and diabetes models in rats, so as to verify the synergistic effect of SAR combined with pCPA, CDP, BSA on the treatment of IR and diabetes .

[0077] 2.1 Experimental method

[0078] (1) Animal handling

[0079] 108 male Wistar rats were randomly divided into 18 groups (6 in each group): control group, IR model group, IR model SAR treatment group, IR model SAR+pCPA compound treatment group (SAR: pCPA in different weight ratios of 4 compound), the IR model pCPA treatment group, the IR model SAR+CDP compound treatment group (SAR:CDP is 4 kinds of compound according to different weight ratios), the IR model CDP treatment group, the IR model SAR+BSA compound treatment group (SAR: 4 compound formulations of BSA according to different weight ratios), IR model BSA treatment group. Animals were...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, in particular to a compound medicine composition for treating II type diabetes or metabolic syndrome and particularly discloses a compound medicine composition formed by combining 5-hydroxytryptamine 2 receptor antagonist sarpogrelate with a 5-hydroxytryptamine synthesis inhibitor. The compound medicine composition can be used for improving insulin resistance so that II type diabetes or metabolic syndrome can be treated.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a compound pharmaceutical composition of a combination of 5-hydroxytryptamine 2 receptor antagonist sagrelate and a 5-hydroxytryptamine synthesis inhibitor. The compound pharmaceutical composition of the present invention can be used to improve insulin resistance so as to treat type II diabetes and metabolic syndrome. Background technique [0002] Insulin resistance (Insulin resistance, IR) refers to the phenomenon that "various reasons cause the efficiency of insulin to promote cell uptake and glucose utilization to decrease, and the body compensatoryly secretes excessive insulin to produce hyperinsulinemia to maintain the stability of blood sugar". In a person with normal metabolism, insulin is secreted by the islet β cells in the pancreas after eating, and it transmits a signal to the insulin-sensing tissue in the body, causing the glucose transporter (Glucosetransporter, GLUT)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/225A61P3/10A61P3/00A61K31/198A61K31/165
Inventor 傅继华李涛郭可可曲伟李鑫安闪闪马少欣
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products